Jim Cramer Says Nvidia, Eli Lilly, Novo Nordisk Are Not Overvalued: 'Will Be Ready To Buy If This Market Sells Off'
Portfolio Pulse from Benzinga Neuro
Jim Cramer, on his CNBC show 'Mad Money', recommended investors to be prepared for a market sell-off, highlighting Nvidia, Eli Lilly, and Novo Nordisk as not overvalued and worth buying on dips. He dismissed sector bubbles, particularly in AI, and endorsed the valuations of these companies despite their high market caps and competition in their respective sectors.
March 05, 2024 | 6:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly, recognized for its GLP-1 medications for diabetes and obesity, is endorsed by Cramer for investment during market dips.
Eli Lilly's strong position in the diabetes and obesity treatment market, despite competition, makes it a solid investment, especially with the ongoing demand for effective treatments.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 85
POSITIVE IMPACT
Nvidia, with a market cap over $2 trillion and consistent earnings beats, is highlighted by Cramer as a strong buy if the market pulls back.
Nvidia's leading position in the AI chip market and consistent performance make it a strong candidate for growth, especially with AI's expanding role in technology.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Novo Nordisk, a leader in diabetes and obesity treatments, is recommended by Cramer as a buy on market sell-offs.
With the increasing prevalence of diabetes and obesity worldwide, Novo Nordisk's focus on GLP-1 medications positions it well for growth, making it a compelling buy on pullbacks.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 85